All In Biotech

Drug Trial Radar · NCT04234048

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

Jun 1, 2028

Study completion Nov 1, 2028

Sponsor

Lead sponsor
SciTech Development, Inc.Industry
Sponsor type
Industry
First posted
Jan 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

Conditions

  • T-cell Lymphoma
  • Cutaneous/Peripheral T-Cell Lymphoma
  • Peripheral T-cell Lymphoma
  • Peripheral T-Cell Lymphoma, Not Classified
  • Primary Cutaneous T-cell Lymphoma
  • Cutaneous T-Cell Lymphoma, Unspecified
  • Cutaneous T-cell Lymphoma
  • Follicular T-Cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma
  • Sézary's Disease
  • Mycosis Fungoides

Interventions

  • FenretinideDrug

    Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

  • City of Hope Medical Foundation

    Duarte, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Barbara Ann Karmanos Cancer Institute Wayne State University

    Detroit, Michigan · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.